Atherosclerosis and the vulnerable plaque-pathogenesis: Part I

Australian and New Zealand Journal of Medicine

Volumn 30, Issue 5, 2000, Pages 600-607

  Worthley, S G ^a   Helft, G ^b   Zaman, A G ^b   Fuster, V ^b   Badimon, J J ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; LIPOPROTEIN; MATRIX METALLOPROTEINASE;

ATHEROSCLEROSIS; BLOOD RHEOLOGY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; FAMILY HISTORY; HUMAN; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; OBESITY; PATHOGENESIS; REVIEW; RISK FACTOR; SMOKING; THROMBOGENESIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INFLAMMATION; LIPOPROTEINS; MUSCLE, SMOOTH, VASCULAR; RHEOLOGY; RISK FACTORS; SMOKING; THROMBOSIS;

EID: 0033778099     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2000.tb00862.x     Document Type: Review

References (34)

1. Atherosclerosis - An inflammatory disease
2. Vascular endothelium, hemodynamic forces, atherogenesis
3. Calcium-dependent and calcium-independent activation of the endothelial NO synthase
4. Matrix metalloproteinases and coronary artery disease: A novel therapeutic target
5. Oxidative stress and cardiovascular disease
6. Macrophages and atherosclerotic plaque stability
7. Low-density lipoprotein density and atherosclerosis. Unraveling the connection
8. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis
9. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation
10. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene
11. Vitamin E consumption and the risk of coronary heart disease in men
12. Vitamin E consumption and the risk of coronary disease in women
13. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)
14. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
15. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
16. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: A randomized, placebo-controlled study
17. High density lipoproteins and coronary heart disease
18. Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction
19. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells
20. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
21. Expression of adhesion molecules by lp(a): A potential novel mechanism for its atherogenicity
22. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix
23. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells
24. Advanced glycation end products, oxidant stress and vascular lesions
25. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction
26. Thromboxane bio-synthesis and platelet function in type II diabetes mellitus
27. Mechanisms of epinephrine-induced platelet aggregation
28. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
29. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
30. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model
31. Association of fibrinolyric parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study
32. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
33. Fibrinogen and cardiovascular disease